Forte Biosciences Current Ratio 2016-2021 | FBRX

Forte Biosciences current ratio from 2016 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Forte Biosciences Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.05B $0.00B 17.42
2021-03-31 $0.06B $0.00B 23.58
2020-12-31 $0.06B $0.00B 26.52
2020-09-30 $0.02B $0.00B 8.97
2020-06-30 $0.03B $0.00B 8.20
2020-03-31 $0.02B $0.01B 1.15
2019-12-31 $0.01B $0.00B 3.93
2019-09-30 $0.06B $0.04B 1.43
2019-06-30 $0.07B $0.02B 4.21
2019-03-31 $0.08B $0.02B 5.05
2018-12-31 $0.10B $0.02B 5.91
2018-09-30 $0.09B $0.02B 5.83
2018-06-30 $0.08B $0.01B 6.06
2018-03-31 $0.08B $0.02B 4.56
2017-12-31 $0.09B $0.02B 5.23
2017-09-30 $0.10B $0.02B 6.02
2017-06-30 $0.11B $0.02B 7.20
2017-03-31 $0.03B $0.02B 1.87
2016-12-31 $0.03B $0.01B 2.26
2016-09-30 $0.00B 0.00
2016-06-30 $0.00B 0.00
2016-03-31 $0.00B 0.00
2015-12-31 $0.06B $0.01B 10.15
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.047B $0.000B
Forte Biosciences Inc. is a clinical stage, dermatology company. It engages in developing biotherapeutic, FB-401, for the treatment of inflammatory skin diseases which is in clinical stage. Forte Biosciences Inc., formerly known as Tocagen Inc., is based in Sherman Oaks, California.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.660B 8.90
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.482B 21.14
Biohaven Pharmaceutical Holding (BHVN) United States $8.764B 0.00
Emergent Biosolutions (EBS) United States $2.892B 6.98
Arcus Biosciences (RCUS) United States $2.573B 0.00
Myovant Sciences (MYOV) United Kingdom $2.051B 0.00
ADC Therapeutics SA (ADCT) Switzerland $2.021B 0.00
Zymeworks (ZYME) Canada $1.443B 0.00
Ambrx Biopharma (AMAM) United States $0.527B 0.00
SQZ Biotechnologies (SQZ) United States $0.417B 0.00
Enzo Biochem (ENZ) United States $0.172B 50.71